Marinus Pharmaceuticals Inc

Change company Symbol lookup

Select an option...

MRNS Marinus Pharmaceuticals Inc

RVLP RVL Pharmaceuticals PLC

NAUT Nautilus Biotechnology Inc

BOF BranchOut Food Inc

SPRC Scisparc Ltd

NRSN Neurosense Therapeutics Ltd

ACNT Ascent Industries Co

FATH Fathom Digital Manufacturing Corp

PAYX Paychex Inc

WAVD Wavedancer Inc

Go

Marinus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is focused on the development of therapeutics for seizure disorders. The Company’s commercial product, ZTALMY (ganaxolone) oral suspension CV, has been approved by the United States Food and Drug Administration (FDA) for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder in patients two years of age and older. The potential of ganaxolone is also being studied in other rare seizure disorders, including in Phase III trials in tuberous sclerosis complex and refractory status epilepticus. The Company's ganaxolone is a neuroactive steroid gamma-aminobutyric acid type A (GABAA) receptor modulator that acts on a well-characterized target in the brain known to have anti-seizure effects. Its ganaxolone is also being developed in IV and oral formulations to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings.